Tech Company Inital Public Offerings
Phathom Pharmaceuticals IPO
On 10/24/2019, Phathom Pharmaceuticals became a public company.
Transaction Overview
Company Name
Announced On
10/24/2019
Transaction Type
IPO
Amount
$182,400,000
Proceeds Purpose
We intend to use approximately $100.0 million of the net proceeds from this offering to fund the clinical development of vonoprazan and the remainder for working capital and general corporate purposes, including pre-commercial activities. We may also use a portion of the remaining net proceeds and our existing cash and cash equivalents to in-license, acquire, or invest in complementary businesses, technologies, products or assets.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
70 Willow Rd. 200
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Undisclosed
Website
Email Address
Overview
Phathom Pharmaceuticals (Nasdaq: PHAT), launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acid blocker (P-CAB).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Tadataka Yamada
Chief Executive Officer
David Socks
Chief Operating Officer
Azmi Nabulsi
Chief Scientific Officer
Roger Ulrich
VP - Bus. Development
Aditya Kohli
Browse more venture capital transactions:
Prev: 10/24/2019: AVIA venture capital transaction
Next: 10/24/2019: Truebill venture capital transaction
Share this article
About Our VC Transactions Data
We document every notable VC transaction. VC investment data records reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs